Zobrazeno 1 - 10
of 76
pro vyhledávání: ''
Autor:
Yukio Miki, Kohei Kotani, Kanako Yoshida, Kenjiro Kimura, Naoshi Odagiri, Sawako Uchida-Kobayashi, Akihiro Tamori, Hiroko Ikenaga, Shoji Kubo, Atsushi Hagihara, Ken Kageyama, Masaru Enomoto, Norifumi Kawada, Akira Yamamoto, Hideki Fujii
Publikováno v:
Oncology. 99(3):186-191
Introduction: Lenvatinib has been approved as a systemic therapy for patients with unresectable hepatocellular carcinoma (HCC). We recently experienced lenvatinib-induced tumor-related hemorrhage in patients with HCC. The full details of tumor-relate
Autor:
Naoki Kamachi, Masahito Nakano, Takashi Niizeki, Takumi Kawaguchi, Takuji Torimura, Shigeo Shimose, Hironori Koga, Yu Noda, Ryoko Kuromatsu, Masatoshi Tanaka, Tomotake Shirono, Shusuke Okamura, Hideki Iwamoto, Akira Kajiwara
Publikováno v:
Oncology. 99:756-765
Background & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate
Autor:
Kazuki Ohya, Kazuaki Chayama, Tomokazu Kawaoka, Masami Yamauchi, Maiko Namba, Takashi Nakahara, Michio Imamura, Kei Morio, Eisuke Murakami, Kenichiro Kodama, Shinsuke Uchikawa, Akira Hiramatsu, Hiroshi Aikata
Publikováno v:
Oncology. 97:75-81
Aim: This study investigated early tumor marker response and treatment response in patients with advanced hepatocellular carcinoma (HCC) treated with lenvatinib. Methods: Twenty patients with advanced HCC who received lenvatinib were enrolled in this
Autor:
Takashi Nakahara, Kazuaki Chayama, Tomokazu Kawaoka, Hirotaka Kohno, Kei Amioka, Nami Mori, Hideyuki Hyogo, Keiji Tsuji, Yosuke Suehiro, Y. Ogawa, Michio Imamura, Masami Yamauchi, Takashi Moriya, Noriaki Naeshiro, Michihiro Nonaka, Takayuki Fukuhara, Hatsue Fujino, Yasuyuki Aisaka, Kensuke Naruto, Yoji Honda, Kenichiro Kodama, Masataka Tsuge, Kei Morio, Keiichi Masaki, Eisuke Murakami, Kikukawa Chihiro, Yuwa Ando, Yuki Yoshikawa, Takahiro Azakami, Yumi Kosaka, Shinsuke Uchikawa, Akira Hiramatsu, Hiroshi Aikata, Hiroshi Kohno, Shintaro Takaki
Publikováno v:
Oncology. 99(8)
Introduction: This study compared clinical outcomes of 2nd- and 3rd-line regorafenib in patients with unresectable hepatocellular carcinoma. Methods: In this retrospective cohort study, 48 patients were treated with regorafenib for unresectable hepat
Autor:
Kenji Tamura, Mayu Yunokawa, Seiko Bun, Yuichi Takiguchi, Takahiro Ebata, Kan Yonemori, Shunichiro Iwasawa, Tatsunori Shimoi, Tsukasa Ishiwata
Publikováno v:
Oncology. 93:177-182
Objective: The aim of this study was to investigate the clinical usefulness of amrubicin therapy for patients with non-gastrointestinal (GI) non-pancreatic extrapulmonary neuroendocrine carcinoma (EP-NEC). Methods: The medical records of patients fro
Publikováno v:
Oncology. 92:291-298
Objective: Esophagogastric cancer occurs more frequently in older patients, but these are underrepresented in clinical studies establishing the current treatment standards for perioperative chemotherapy in locally advanced disease. This leads to unce
Autor:
Masataka Tsuge, Michio Imamura, Fumi Honda, Yuko Nagaoki, Yoshiiku Kawakami, Kei Morio, Yuji Teraoka, Kazuaki Chayama, Tomokazu Kawaoka, Reona Morio, Tomoki Kobayashi, Takashi Nakahara, Yuki Inagaki, Akira Hiramatsu, Masahiro Hatooka, Hiroshi Aikata
Publikováno v:
Oncology. 92:335-346
Objective: To evaluate the impact of hepatitis C virus (HCV) eradication on the clinical outcome of patients with HCV-related advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods: A total of 58 HCV-related advanced HCC patients wit
Autor:
Hirohito Yoneyama, Yasunori Minami, Joji Tani, Atsushi Kubo, Kazuomi Ueshima, Chikara Ogawa, Akio Moriya, Masaharu Ando, Akihiro Deguchi, Kouichi Takaguchi, Naoshi Nishida, Toshihiro Matsunaka, Mitsushige Shibatoge, Asahiro Morishita, Akemi Tsutsui, Toshiharu Sakurai, Hiroyuki Tamaki, Akina Omura, Teruyo Noda, Tsutomu Masaki, Masahiro Morita, Yasutaka Kokudo, Masatoshi Kudo, Takuya Nagano, Tomonori Senoh
Publikováno v:
Oncology. 93:113-119
Objective: To determine the relationship between treatment outcomes and hand-foot syndrome (HFS), and the relationship between survival rate and post-progression treatment after sorafenib therapy. Methods: The study assessed 314 patients with advance
Autor:
Lisa Sautter, Ralf Hofheinz, Frederik Wenz, Andreas Hochhaus, Jochen Tuettenberg, Frank A. Giordano, Christoph Groden, Mario Grimm, Peter Vajkoczy, Kirsten Schmieder
Publikováno v:
Oncology. 98(1)
Purpose:Preclinical studies indicated that imatinib may have single-agent activity in glioblastoma through inhibition of tyrosine kinase activity and also that it might enhance the efficacy of radiotherapy. We therefore sought to investigate clinical
Autor:
Hidemi Goto, Isao Nakano, Kazuhiko Hayashi, Yoji Ishizu, Tetsuya Ishikawa, Teiji Kuzuya, Takashi Honda, Yoshiki Hirooka, Masatoshi Ishigami
Publikováno v:
Oncology. 91:261-266
Objectives: The aim of this study was to investigate the relationship between fever within 2 weeks after the start of sorafenib therapy and treatment efficacy in patients with advanced hepatocellular carcinoma (HCC). Methods: One hundred and two pati